| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2013 | EP2560942A1 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis |
| 02/27/2013 | EP2560734A2 Cosmetic or dermatological preparations containing combinations of magnolia bark extract and acyl glutamates |
| 02/27/2013 | EP2560732A2 A solid pharmaceutical composition for neutralizing stomach acid |
| 02/27/2013 | EP2560688A1 Combination of drugs with protein-binding prodrugs |
| 02/27/2013 | EP2560676A1 Organic compounds |
| 02/27/2013 | EP2560666A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate) |
| 02/27/2013 | EP2560665A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates |
| 02/27/2013 | EP2560662A2 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved |
| 02/27/2013 | EP2560661A2 Use of the modified polysaccharides for heparin neutralization |
| 02/27/2013 | EP2560660A1 Chemosensory receptor ligand-based therapies |
| 02/27/2013 | EP2560659A2 Compositions and method for the treatment of multiple myeloma |
| 02/27/2013 | EP2560658A2 Methods of enhancing antibody-dependent cellular cytotoxicity |
| 02/27/2013 | EP2560657A2 Anti-viral compounds |
| 02/27/2013 | EP2560656A2 Anti-viral compounds |
| 02/27/2013 | EP2560655A1 Substituted pyrimidines |
| 02/27/2013 | EP2560654A1 Compounds, compositions and methods comprising pyridazine sulfonamide derivatives |
| 02/27/2013 | EP2560653A1 Certain amino-pyrimidines, compositions thereof, and methods for their use |
| 02/27/2013 | EP2560652A2 Anti-viral compounds |
| 02/27/2013 | EP2560651A1 Pharmaceutical compositions and administrations thereof |
| 02/27/2013 | EP2560650A1 Pharmaceutical compositions and administrations thereof |
| 02/27/2013 | EP2560649A1 Pharmaceutical compositions and administrations thereof |
| 02/27/2013 | EP2560648A2 Method for treating pancreatic cancer |
| 02/27/2013 | EP2560647A2 Combination therapy with a proteasome inhibitor and a gallium complex |
| 02/27/2013 | EP2560646A2 Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain |
| 02/27/2013 | EP2560645A2 Novel conjugates of cc-1065 analogs and bifunctional linkers |
| 02/27/2013 | EP2560644A1 A pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent |
| 02/27/2013 | EP2560643A1 Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
| 02/27/2013 | EP2560642A2 Treatment of gout |
| 02/27/2013 | EP2560641A2 Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| 02/27/2013 | EP2560640A1 Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| 02/27/2013 | EP2560639A2 Method of treating prostate cancer |
| 02/27/2013 | EP2560638A2 Method of treating gastric cancer |
| 02/27/2013 | EP2560637A2 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| 02/27/2013 | EP2560636A2 Anti-viral compounds |
| 02/27/2013 | EP2560635A2 Anti-viral compounds |
| 02/27/2013 | EP2560634A1 Nitric oxide releasing prodrugs of therapeutic agents |
| 02/27/2013 | EP2560633A2 Intravenous omega-3 fatty acid compositions & method of use |
| 02/27/2013 | EP2560632A1 Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them |
| 02/27/2013 | EP2560631A2 Baclofen and acamprosate based therapy of neurogical disorders |
| 02/27/2013 | EP2560630A2 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment |
| 02/27/2013 | EP2560629A2 Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
| 02/27/2013 | EP2560628A2 Anti-viral compounds |
| 02/27/2013 | EP2560627A1 Use of bis [thiohydrazide amide]compounds such as elesclomol for treating cancers |
| 02/27/2013 | EP2560626A1 Local anesthetic emulsion compositions and methods of making and using the same |
| 02/27/2013 | EP2560625A2 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| 02/27/2013 | EP2560624A1 Therapeutic formulation for reduced drug side effects |
| 02/27/2013 | EP2560623A1 Oral sustained release formulation of huperzine a |
| 02/27/2013 | EP2560622A1 Pramipexole-containing matrix tablet |
| 02/27/2013 | EP2560621A1 Fingolimod in the form of a solid solution |
| 02/27/2013 | EP2560620A2 A process for particle processing of active pharmaceutical ingredients |
| 02/27/2013 | EP2560619A2 A method of preparing an oral dosage form comprising fingolimod |
| 02/27/2013 | EP2560618A1 Melt-granulated fingolimod |
| 02/27/2013 | EP2560617A2 Pharmaceutical compositions |
| 02/27/2013 | EP2560616A2 Artificial tear emulsion |
| 02/27/2013 | EP2560615A1 Thiazolidinedione analogues |
| 02/27/2013 | EP2560614A1 Pharmaceutical compositions and methods for administering the same |
| 02/27/2013 | EP2560610A1 Taste masked dosage form of pharmaceutically acceptable salt of escitalopram |
| 02/27/2013 | EP2560493A1 An enantioselective process for cycloalkenyl b-substituted alanines |
| 02/27/2013 | EP2560491A1 Peripheral opioid agonists and peripheral opioid antagonists |
| 02/27/2013 | EP2560490A1 Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| 02/27/2013 | EP2560489A1 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| 02/27/2013 | EP2560488A1 Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| 02/27/2013 | EP2560486A1 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| 02/27/2013 | EP2143444A9 Compositions for inhibition of angiogenesis |
| 02/27/2013 | DE202012012289U1 Dialysier und Substitutionsflüssigkeit Dialysier and substitution fluid |
| 02/27/2013 | CN1950098B Biodegradable polyurethane and polyurethane ureas |
| 02/27/2013 | CN1886385B Crystals of phenylalanine derivatives and production methods thereof |
| 02/27/2013 | CN102947451A Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| 02/27/2013 | CN102947446A Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma |
| 02/27/2013 | CN102947322A Anticancer steroidal lactones unsaturated in position 7 (8) |
| 02/27/2013 | CN102947321A New low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses |
| 02/27/2013 | CN102947316A Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| 02/27/2013 | CN102947315A Inhibitors of protein tyrosine kinase activity |
| 02/27/2013 | CN102947313A Pyripyropene derivative having acat2 inhibiting activity and stable to metabolizing enzymes |
| 02/27/2013 | CN102947311A 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators |
| 02/27/2013 | CN102947310A Anellated pyridine compounds as dual modulators of the 5-HT2A and D3 receptors |
| 02/27/2013 | CN102947309A 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof |
| 02/27/2013 | CN102947308A Polymorphs of OSI-906 |
| 02/27/2013 | CN102947307A Novel antifungal 5,6-dihydro-4-[(difluoroethyl)phenyl]-4h-pyrrolo[1,2-a][1,4]benzodiazepine and 4-(difluoroethyl)phenyl-6h-pyrrolo[1,2-a][1,4]benzodiazepine derivatives |
| 02/27/2013 | CN102947306A 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as SYK inhibitors |
| 02/27/2013 | CN102947305A Compounds and methods for kinase modulation, and indications therefor |
| 02/27/2013 | CN102947302A Triazolo [4, 5 - b] pyridin derivatives |
| 02/27/2013 | CN102947301A Quinolizidine and indolizidine derivatives |
| 02/27/2013 | CN102947300A Alkaloid aminoester derivatives and medicinal compositions thereof |
| 02/27/2013 | CN102947299A Alkaloid aminoester derivatives and medicinal composition thereof |
| 02/27/2013 | CN102947298A Alkaloid aminoester derivatives and medicinal composition thereof |
| 02/27/2013 | CN102947297A Amido-tropane derivatives |
| 02/27/2013 | CN102947295A 3,3-disubstituted-(8-aza-bicyclo [3.2.1]oct-8-y)-[5-(1 -pyrazol-4-yl)-thiophe-3-yl] methanones as inhibitors of 11[beta]-HSD1 |
| 02/27/2013 | CN102947292A Nitrogen containing heteroaryl compounds |
| 02/27/2013 | CN102947291A Prodrug of triazolone compound |
| 02/27/2013 | CN102947290A Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| 02/27/2013 | CN102947289A Arylethynyl derivatives |
| 02/27/2013 | CN102947288A Dithiin derivatives as fungicides |
| 02/27/2013 | CN102947287A Cysteamine derivatives and their use in the treatment of nash |
| 02/27/2013 | CN102947285A Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 02/27/2013 | CN102947283A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 02/27/2013 | CN102947281A Novel aminoalkyl-oxazole and aminoalkyl-thiazole carboxylic acid amides as regeneration-promoting substances for sensory organs and post-mitotic tissue |
| 02/27/2013 | CN102947280A Carboxy oxazole or thiazole compounds as dgat - 1 inhibitors useful for the treatment of obesity |
| 02/27/2013 | CN102947275A Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| 02/27/2013 | CN102947274A Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |